NCT03044353View on ClinicalTrials.gov

Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698

PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

July 10, 2017

Primary Completion Date

January 3, 2019

Study Completion Date

January 3, 2019

Conditions
Amyloidosis
Interventions
DRUG

GSK2315698 (CPHPC)

20mg/hour, IV (in the vein) for up to 72hours followed by 60mg three times daily subcutaneous injection for 11 days. Number of cycles: up to 6. Dose level and frequency adjusted according to renal function

BIOLOGICAL

GSK2398852 (anti-SAP mAb)

Up to 1200mg, IV divided over days 1 and 3. Number of cycles: up to 6. Dose level adjusted based on tolerability.

Trial Locations (3)

02115

GSK Investigational Site, Boston

CB2 0GG

GSK Investigational Site, Cambridge

NW10 7EW

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT03044353 - Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698 | Biotech Hunter | Biotech Hunter